Vanguard Group Inc. Decreases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Vanguard Group Inc. reduced its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,036,183 shares of the specialty pharmaceutical company’s stock after selling 71,326 shares during the period. Vanguard Group Inc. owned 0.10% of Jazz Pharmaceuticals worth $743,356,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JAZZ. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $9,335,000. Moloney Securities Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $464,000. Franklin Resources Inc. lifted its position in shares of Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after acquiring an additional 48,708 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 13.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock valued at $4,420,000 after acquiring an additional 4,332 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Needham & Company LLC reissued a “buy” rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Piper Sandler reiterated an “overweight” rating and set a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Finally, Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,022,825 over the last quarter. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $122.92 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The firm’s 50-day simple moving average is $132.30 and its 200-day simple moving average is $122.54. The firm has a market cap of $7.47 billion, a PE ratio of 17.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.